- Kuria's Chief Executive Officer and Chief Development Officer to share ophthalmic program updates and present corporate overview
Kuria Therapeutics, a pharmaceutical company developing a platform of novel Nrf2 activators for ophthalmic disease, will be holding meetings with investors and other parties during the 42nd Annual J.P. Morgan Healthcare Conference, January 8-11 2024, in San Francisco, California.
Kuria's Chief Executive Officer, Dr. Keith Ward, and Chief Development Officer, Dave Flory, will be holding one-on-one meetings during the conference. Dr. Ward and Mr. Flory will discuss the latest company and data updates for Kuria's program developing novel Nrf2 activators to Power Sight in blinding diseases of the retina and cornea.
For scheduling requests, email KuriaJPM@kuriatx.com.
About Kuria Therapeutics, Inc.: Kuria Therapeutics, Inc. is a US-based pharmaceutical company dedicated to the development of novel therapeutics for ophthalmic disease. We are a team of seasoned life science executives and entrepreneurs with decades of experience in building biotechnology companies, running complex multi-national development programs, managing alliances with partners, and building relationships with clinicians, investors, vendors, and patient groups. For more information, visit www.kuriatx.com.
Contacts Investor Relations and Media Kuria Therapeutics: Corporate Communication email@example.com